ByTrending Posts
Is the OBI Pharma–TegMine Therapeutics ADC Deal the…
Key Highlights 1. Powering the Next-Gen ADC Revolution: OBI’s GlycOBI® Meets TegMine’s TegMiner™The collaboration between Taiwan-based OBI Pharma…
Can AI Reveal the Hidden Biology of Cancer?…
Key Highlights: AI Collaboration to Decode Cancer ComplexityIn a bold step to redefine cancer treatment, Aitia, a leader…
Is Juvenescence’s Acquisition of Ro5 the Key to…
Key Insights Juvenescence Acquires Ro5 to Bolster AI Capabilities in Drug DiscoveryJuvenescence Limited, a clinical-stage AI-enabled biotech company,…
Can AI Turn Biobank Data into Precision Drug…
Key Highlights Transforming Biobanks into AI-Driven EnginesElucidata, a U.S.-India based AI pioneer in life sciences, and Sapien Biosciences,…
How Will Axxam and Molecular Health’s AI-Powered Alliance…
Key Highlights: Strategic Collaboration Targets Early Drug Discovery BottlenecksAnnounced on June 4, 2025, Molecular Health and Axxam have…
Can Clairity’s FDA-Approved AI Breast Cancer Prediction Tool…
Key Highlights: AI-Driven Risk Prediction: A Breakthrough in Preventive OncologyBoston-based Clairity received FDA de novo authorization for Clairity…
MedInvest 2025: How NeuroOne’s AI-Enabled Brain Stimulation and…
Key Highlights: 1. NeuroOne’s Vision: AI for Real-World Neurological DisordersNeuroOne will join MedInvest’s MedTech, AI & Digital Health…
How CareCloud Is Applying AI to Transform Clinical…
Key Highlights CareCloud to Join Elite Healthcare IT Panel at Maxim ConferenceCareCloud, Inc. (Nasdaq: CCLD, CCLDO), a leading…
How Insilico’s AI-Discovered Drug Achieved a Landmark Clinical…
Key Highlights:• Insilico Medicine’s AI-driven drug discovery platform Pharma.AI enabled rapid development of Rentosertib, a novel TNIK inhibitor…
Trending Posts
Latest Stories
Do Wegovy Pricing Pathways in 2026 Signal a Turning Point for Obesity Drug Access and Market Expansion?
Global – December 2025 — A new pricing and access analysis for Wegovy (semaglutide) highlights…
Does FDA Approval of Nereus Mark a Long-Awaited Breakthrough for Motion-Sickness Treatment—and a Turning Point for Vanda Pharmaceuticals?
Washington, D.C. – December 2025 — Vanda Pharmaceuticals achieved a major regulatory milestone after the…
Will Axsome Therapeutics’ FDA Priority Review of AXS-05 Address a Long-Standing Gap in Alzheimer’s Disease Agitation Treatment?
New York – December 31, 2025 — Axsome Therapeutics has reached a major regulatory milestone…
Can Dual Regulatory Approvals Position UltraGreen.ai as a Regional Leader in Fluorescence-Guided and AI-Enabled Surgery in Southeast Asia?
Singapore – December 31, 2025 — UltraGreen.ai Limited, a Singapore-based company specializing in fluorescence-guided surgery…
Gallery
